February 16, 2021 -- Contract research organization Avance Biosciences is expanding its Houston facility to meet growing demand for cell-based manufacturing.
The new facility is located adjacent to the company's existing facility and is expected to be completed in the third quarter of 2021. The additional 5,500 sq ft will be devoted to cell-based assay services and enable Avance to better address client needs related to good manufacturing practices.
Additionally, the company is expanding its mammalian cell culture-related assay capabilities, including mycoplasma testing, adventitious agents testing, sterility, and potency.
In 2020, Avance added 7,500 sq ft dedicated to next-generation sequencing and droplet digital polymerase chain reaction (PCR) capabilities to support edited gene testing, gene integration assays, and DNA/RNA biodistribution studies for gene therapy clients.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
